Oncolytics Biotech Inc.
ONC.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.18M | 9.54M | 9.72M | 10.03M | 11.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.29M | 23.95M | 25.55M | 26.02M | 27.00M |
| Operating Income | -22.29M | -23.95M | -25.55M | -26.02M | -27.00M |
| Income Before Tax | -21.75M | -22.59M | -23.05M | -20.21M | -20.61M |
| Income Tax Expenses | 86.60K | 94.60K | 94.60K | 109.80K | 106.20K |
| Earnings from Continuing Operations | -21.84 | -22.69 | -23.14 | -20.32 | -20.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.84M | -22.69M | -23.14M | -20.32M | -20.72M |
| EBIT | -22.29M | -23.95M | -25.55M | -26.02M | -27.00M |
| EBITDA | -22.22M | -23.88M | -25.47M | -25.94M | -26.93M |
| EPS Basic | -0.27 | -0.29 | -0.30 | -0.27 | -0.28 |
| Normalized Basic EPS | -0.17 | -0.18 | -0.19 | -0.17 | -0.18 |
| EPS Diluted | -0.27 | -0.29 | -0.30 | -0.27 | -0.28 |
| Normalized Diluted EPS | -0.17 | -0.18 | -0.19 | -0.17 | -0.18 |
| Average Basic Shares Outstanding | 330.22M | 315.31M | 305.92M | 302.15M | 294.94M |
| Average Diluted Shares Outstanding | 330.22M | 315.31M | 305.92M | 302.15M | 294.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |